- Condition: Polycystic Ovary Syndrome
Intervention:
Sponsors: Taipei Medical University WanFang Hospital; Taipei Medical University WanFang Hospital
Recruiting - verified May 2012 - Conditions: Oxidative Stress; Endocrine-Disrupting Chemicals; Polycystic Ovary Syndrome
Intervention:
Sponsors: Taipei Medical University WanFang Hospital; Ming-I Hsu
Recruiting - verified May 2012 - Conditions: Kallmann Syndrome; Hypogonadotropic Hypogonadism; Hypothalamic Amenorrhea; Polycystic Ovarian Syndrome; Precocious Puberty
Intervention:
Sponsors: Centre Hospitalier Universitaire Vaudois; Centre Hospitalier Universitaire Vaudois; Swiss National Science Foundation
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Intervention: Drug: pazopanib in combination with weekly topotecan
Sponsors: Charite University, Berlin, Germany; JSehouli; GlaxoSmithKline
Not yet recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Other: Neuroimaging & Neuropsychological Evaluation; Other: Neuroimaging & Neuropsychological Evaluation
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University
Recruiting - verified May 2012 - Conditions: Pregnancy; Polycystic Ovary Syndrome
Interventions: Drug: Metformin; Drug: placebo
Sponsors: Norwegian University of Science and Technology; Norwegian University of Science and Technology; Landspitali University Hospital; Uppsala University Hospital; Haukeland University Hospital; Karolinska University Hospital; Odense University Hospital; St. Olavs Hospital; Sykehuset Telemark; Stockholm South General Hospital
Not yet recruiting - verified April 2012 - Conditions: Cancer Survivor; Breast Cancer; Colorectal Cancer; Gynecological Cancer; Ovarian Cancer; Uterine Cancer
Intervention: Behavioral: Mindfulness Based Cancer Recovery
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified May 2012 - Condition: Granulosa Cell Tumour of the Ovary
Intervention: Drug: Ketoconazole
Sponsors: Grupo Español de Tumores Huérfanos e Infrecuentes; Grupo Español de Tumores Huérfanos e Infrecuentes
Not yet recruiting - verified April 2012 - Conditions: Cancer.; Melanoma.; Ovarian Cancer.; Lung Cancer.
Interventions: Biological: NY-ESO-1 combined with MPLA; Biological: NY-ESO-1 combined with MPLA vaccine
Sponsors: Instituto de Investigação em Imunologia; Instituto de Investigação em Imunologia; Butantan Institute
Not yet recruiting - verified April 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Cervical Cancer; Endometrial Cancer; Esophageal Cancer; Fallopian Tube Cancer; Gastric Cancer; Ovarian Cancer; Sarcoma; Vaginal Cancer; Vulvar Cancer
Intervention:
Sponsors: Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of Surrey
Recruiting - verified April 2012 - Condition: Ovarian Cancer
Interventions: Drug: vargatef; Drug: placebo
Sponsors: ARCAGY/ GINECO GROUP; ARCAGY/ GINECO GROUP
Not yet recruiting - verified April 2012 - Conditions: Ovarian Cancer; Endometrial Cancer
Interventions: Biological: E39 peptide vaccine; Other: Clinical tracking for disease progression/recurrence
Sponsors: San Antonio Military Medical Center; COL George Peoples, MD, FACS
Recruiting - verified April 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Placebo; Drug: Inositol
Sponsors: Catholic University of the Sacred Heart; Catholic University of the Sacred Heart
Recruiting - verified April 2012 - Conditions: Polycystic Ovary Syndrome; Insulin Resistance
Interventions: Drug: Metformin; Drug: Ethinylestradiol and Cyproterone Acetate
Sponsors: Chongqing Medical University; Chongqing Medical University
Recruiting - verified April 2012 - Conditions: Female Infertility; Ovarian Insufficiency
Interventions: Drug: Serophene High Dose; Drug: Serophene Low Dose; Drug: Placebo High Dose; Drug: Placebo Low dose
Sponsors: University Hospital, Basel, Switzerland; University Hospital, Basel, Switzerland
Not yet recruiting - verified April 2012 - Conditions: Pregnancy; Polycystic Ovary Syndrome; Infertility
Interventions: Other: Acupuncture treatment 1; Other: Acupuncture treatment 2; Other: CC; Other: CC placebo
Sponsors: Heilongjiang University of Chinese Medicine; Heilongjiang University of Chinese Medicine; Yale University; Penn State University; Göteborg University; The University of Hong Kong; Beijing University of Chinese Medicine; Sichuan University; Second Affiliated Hospital，Heilongjiang University of Chinese Medicine; First Affiliated Hospital of Harbin Medical University; Forth Affiliated Hospital of Harbin Medical University; The Daqing Oilfield General Hospital; Daqing LongNa Hospital; Mudanjiang Women And Children's Hospital; First Affiliated Hospital，Changchun University of Chinese Medicine; Liaoning University of Chinese Medicine Affiliated Hospital; First Affiliated Hospital，Tianjin University of Chinese Medicine; Second Affiliated Hospital，Changchun University of Chinese Medicine; Tianjin Tanggu Maternity and Child Care Center; Tianjin Tanggu Chinese Medicine Hospital; Wenzhou Zhongshan Hospital; Wenzhou Chinese Medicine Hospital; Integrated Chinese and Western Medicine Hospital of Zhejiang Province; Hangzhou Chinese Medicine Hospital; Shanxi Chinese Medicine Hospital; Henan Chinese Medicine Hospital; Maternal and Child Health Hospital of Xuzhou; Maternal and Child Health Hospital of Suqian; Maternal and Child Health Hospital of Huaian; First Affiliated Hospital，Anhui University of Chinese Medicine; Suzhou Chinese Medicine Hospital; Wuhan TongJi Hospital; Hubei Chinese Medicine Hospital; Shanxi University of Chinese Medicine Affiliated Hospital; Jiangxi University of Chinese Medicine Affiliated Hospital; First Affiliated Hospital，Hunan University of Chinese Medicine; First Affiliated Hospital，Guangzhou University of Chinese Medicine; Guangdong Chinese Hospital; Guangzhou Liwan Chinese Hospital; Dalian maternity hospital
Not yet recruiting - verified April 2012 - Condition: Adverse Effect of Oral Contraceptives, Sequela
Intervention: Drug: oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel
Sponsors: University of Oulu; University of Oulu
Recruiting - verified May 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Procedure: management of therapy complications; Procedure: musculoskeletal complications management/prevention
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Not yet recruiting - verified May 2012 - Condition: Ovarian Cancer
Interventions: Biological: T cells; Biological: T cells
Sponsors: University of Pennsylvania; University of Pennsylvania; Roswell Park Cancer Institute; Adaptimmune Ltd.
Recruiting - verified April 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Biological: TroVax®; Biological: Placebo
Sponsors: University College, London; University College, London; Oxford BioMedica; Cancer Research UK
Not yet recruiting - verified March 2012 - Conditions: Polycystic Ovary Syndrome; Hirsutism; Menstrual Irregularity
Interventions: Drug: myo-inositol 1500 gr; Drug: myo-inositol 2000 gr + folic acid 200 mcg
Sponsors: Catholic University of the Sacred Heart; Catholic University of the Sacred Heart
Recruiting - verified March 2012 - Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to StandCondition: Epithelial Ovarian Cancer
Interventions: Other: Standard Surgical resection; Device: LIGASURE
Sponsors: University of Utah; University of Utah
Recruiting - verified March 2012 - Condition: Stage IIIC Ovarian Cancer
Interventions: Biological: FANG™ Vaccine; Drug: Bevacizumab
Sponsors: Gradalis, Inc.; Gradalis, Inc.
Recruiting - verified March 2012 - Condition: Ovarian Cancer
Intervention:
Sponsors: University of Washington; University of Washington
Recruiting - verified February 2012 - Condition: Recurrent Ovarian Cancer
Intervention: Drug: Ketoconazole and HPR/LXS
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; South Plains Oncology Consortium
Not yet recruiting - verified February 2012 - Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: veliparib; Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: First Recurrence of Ovarian Cancer
Interventions: Procedure: Secondary citoreduction; Procedure: Hyperthermic intra-peritoneal chemotherapy (HIPEC)
Sponsors: Catholic University of the Sacred Heart; Catholic University of the Sacred Heart
Recruiting - verified February 2012 - Conditions: Cancer; Risk of Premature Ovarian Failure; Fertility Preservation
Intervention: Procedure: surgery to remove ovaries or high dose chemotherapy
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012 - Condition: Ovarian Hyperstimulation Syndrome
Interventions: Drug: Cabergoline; Drug: Placebo
Sponsors: KK Women's and Children's Hospital; KK Women's and Children's Hospital
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Cancer of Ovary; Cancer of the Ovary; Ovary Neoplasms; Primary Peritoneal Carcinoma
Intervention: Drug: Fenretinide/LXS + Ketoconazole
Sponsors: South Plains Oncology Consortium; South Plains Oncology Consortium
Recruiting - verified February 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Low Risk Metastatic Gestational Trophoblastic Tumor; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Gestational Trophoblastic Tumor; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: atorvastatin calcium; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Conditions: Ovarian Cancer; Endometrial Cancer; Uterine Cervical Cancer
Interventions: Drug: Filgrastim; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Belgian Gynaecological Oncology Group; Belgian Gynaecological Oncology Group
Recruiting - verified March 2012 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsConditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Primary Hepatocellular Carcinoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Hormone-resistant Prostate Cancer; Limited Stage Small Cell Lung Cancer; Localized Resectable Adult Primary Liver Cancer; Male Breast Cancer; Mast Cell Sarcoma; Ovarian Sarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Esophageal Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Gastric Cancer; Recurrent Kaposi Sarcoma; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Osteosarcoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Small Intestine Leiomyosarcoma; Stage I Colon Cancer; Stage I Rectal Cancer; Stage I Uterine Sarcoma; Stage IA Breast Cancer; Stage IA Gastric Cancer; Stage IA Ovarian Epithelial Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Breast Cancer; Stage IB Gastric Cancer; Stage IB Ovarian Epithelial Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Ovarian Epithelial Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Breast Cancer; Stage II Uterine Sarcoma; Stage IIA Colon Cancer; Stage IIA Gastric Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Esophageal Cancer; Stage IIB Gastric Cancer; Stage IIB Melanoma; Stage IIB Non-small Cell Lung Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Melanoma; Stage IIC Ovarian Epithelial Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIC Rectal Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Colon Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Gastric Cancer; Stage IIIA Melanoma; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Rectal Cancer; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Gastric Cancer; Stage IIIB Melanoma; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Rectal Cancer; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Gastric Cancer; Stage IIIC Melanoma; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Rectal Cancer; Stage IV Bladder Cancer; Stage IV Esophageal Cancer; Stage IV Gastric Cancer; Stage IV Melanoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus; Other: laboratory biomarker analysis; Biological: DEC-205-NY-ESO-1 fusion protein vaccine
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Conditions: Primary Peritoneal Carcinoma; Ovarian Carcinoma; Fallopian Tube Carcinoma
Intervention: Drug: neoadjuvant chemotherapy
Sponsors: University of Kentucky; University of Kentucky
Recruiting - verified May 2012 - Condition: Epithelial Ovarian Cancer
Interventions: Biological: Placebo Study Agent; Biological: Cvac
Sponsors: Prima BioMed Ltd; Prima BioMed Ltd
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Intervention: Drug: EC-17
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified January 2012 - Conditions: Polycystic Ovarian Syndrome; Infertility; Obesity; Overweight
Interventions: Behavioral: Low-fat, Low-Glycemic Index, Vegan diet; Behavioral: Low Calorie
Sponsors: University of South Carolina; University of South Carolina; American Dietetic Association
Recruiting - verified March 2012 - Conditions: Breast Cancer; Non-small Cell Lung Cancer; Colorectal Cancer; Ovarian Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting - verified March 2012 - Conditions: Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer
Interventions: Drug: Propranolol; Drug: Chemotherapy; Procedure: Surgery; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Moxonidine; Drug: Placebo
Sponsors: Baker IDI Heart and Diabetes Institute; Baker IDI Heart and Diabetes Institute
Not yet recruiting - verified January 2012 - Conditions: Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Primary Peritoneal Cavity Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Primary Peritoneal Cavity Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Epithelial Cancer; Stage IIC Primary Peritoneal Cavity Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer
Interventions: Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; Drug: sirolimus; Other: laboratory biomarker analysis; Biological: sargramostim
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Interventions: Drug: Paclitaxel(intravenous) + Carboplatin(intravenous); Drug: Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
Sponsors: Gynecologic Oncology Trial & Investigation Consortium; Gynecologic Oncology Trial & Investigation Consortium; Japanese Gynecologic Oncology Group
Recruiting - verified January 2012 - Condition: Ovarian Hyperstimulation Syndrome
Interventions: Drug: hCG; Drug: triptorelin; Drug: Triptorelin, estradiol valerate, micronized vaginal progesterone; Drug: triptorelin, hCG; Drug: triptorelin, hCG; Drug: triptorelin, recombinant LH
Sponsors: Instituto Valenciano de Infertilidad, Spain; Instituto Valenciano de Infertilidad, Spain
Recruiting - verified December 2011 - Conditions: Fallopian Tube Cancer; Fatigue; Neuropathy; Neurotoxicity; Ovarian Cancer; Pain; Primary Peritoneal Cavity Cancer
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Conditions: Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Malignant Tumor of Peritoneum; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor
Interventions: Radiation: stereotactic body radiation therapy; Procedure: positron emission tomography; Procedure: computed tomography; Other: questionnaire administration; Radiation: fludeoxyglucose F 18
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: EGEN-001; Drug: pegylated liposomal doxorubicin hydrochloride; Genetic: RNA analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Salsalate; Drug: Salsalate
Sponsors: Indiana University; Indiana University
Recruiting - verified February 2012 - Condition: Ovarian Cancer Recurrent
Interventions: Drug: EP-100; Drug: Paclitaxel
Sponsors: Esperance Pharmaceuticals Inc; Esperance Pharmaceuticals Inc
Recruiting - verified May 2012 - Condition: Ovarian Epithelial Carcinoma
Intervention: Drug: PD0332991
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center
Recruiting - verified March 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Dietary Supplement: Cinnamon Extract; Dietary Supplement: Placebo
Sponsors: Columbia University; Columbia University; Integrity Nutraceuticals International
Recruiting - verified November 2011 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Metformin; Behavioral: Dietary Restriction; Behavioral: Exercise Training
Sponsors: Pennington Biomedical Research Center; Pennington Biomedical Research Center; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012 - Conditions: Female Infertility; Polycystic Ovary Syndrome; Obesity
Intervention: Behavioral: Interdisciplinary lifestyle intervention
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke; Fonds de la Recherche en Santé du Québec
Recruiting - verified November 2011 - Conditions: Metastatic Solid Tumor; Breast Cancer; Ovarian Cancer
Intervention: Drug: Rucaparib
Sponsors: Clovis Oncology, Inc.; Clovis Oncology, Inc.
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Peritoneal Metastases
Intervention:
Sponsors: Institute of Cancer Research, United Kingdom; Institute of Cancer Research, United Kingdom; Cancer Research UK; Royal Marsden NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Imperial College Healthcare NHS Trust; Northumbria Healthcare NHS Foundation Trust
Not yet recruiting - verified March 2012 - Conditions: Polycystic Ovary Syndrome; Normal Volunteers
Intervention: Drug: IVF Antagonist Protocol
Sponsors: University of Cincinnati; University of Cincinnati; Merck
Not yet recruiting - verified December 2011 - Conditions: Obese; Infertility; Polycystic Ovary Syndrome
Interventions: Procedure: IVM (In Vitro Maturation) Treatment; Procedure: IVF (In Vitro Fertilization) Antagonist Protocol
Sponsors: Hillel Yaffe Medical Center; Hillel Yaffe Medical Center
Not yet recruiting - verified April 2012 - Condition: Ovarian Neoplasm
Intervention:
Sponsors: HaEmek Medical Center, Israel; HaEmek Medical Center, Israel; Women and Infants Hospital of Rhode Island
Recruiting - verified November 2011 - Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Behavioral: geriatric assessment and telephone call from nurse; Other: geriatric assessment and no call from nurse
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012 - Conditions: Polycystic Ovary Syndrome; Insulin Resistance; Insulin Sensitivity; Obesity; Pregnancy
Intervention:
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Center on Minority Health and Health Disparities (NCMHD)
Recruiting - verified November 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Pancreatic Cancer
Intervention: Drug: DMOT4039A
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Conditions: Genital Diseases, Female; Ovarian Diseases; Ovarian Neoplasms; Endometrial Neoplasms
Intervention: Drug: Temsirolimus
Sponsors: AGO Study Group; AGO Study Group
Recruiting - verified March 2012 - Conditions: Genital Diseases, Female; Ovarian Diseases; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms
Interventions: Biological: Bevacizumab; Biological: Bevacizumab; Drug: Paclitaxel; Drug: Carboplatin; Other: specialized pathology review (Germany only)
Sponsors: AGO Study Group; AGO Study Group; ARCAGY/ GINECO GROUP; Nordic Society for Gynaecologic Oncology
Recruiting - verified November 2011 - Condition: Adnexal Mass
Intervention:
Sponsors: Fujirebio Diagnostics, Inc.; Fujirebio Diagnostics, Inc.
Not yet recruiting - verified November 2011 - Condition: Recurrent, Epithelial Ovarian Cancer
Intervention: Drug: Veliparib
Sponsors: Vejle Hospital; Vejle Hospital; Abbott
Recruiting - verified December 2011 - Condition: Polycystic Ovary Syndrome
Interventions: Behavioral: Stress reduction; Behavioral: Stress reduction with Health education
Sponsors: Penn State University; Nazia Raja-Khan; National Center for Complementary and Alternative Medicine (NCCAM); Thomas Jefferson University
Recruiting - verified March 2012 - Condition: Ovarian Cancer
Intervention:
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified April 2011 - Condition: Advanced Ovarian Cancer
Interventions: Drug: Neoadjuvant chemotherapy; Drug: Carboplatin
Sponsors: Asan Medical Center; Asan Medical Center; Sanofi-Aventis
Recruiting - verified October 2011 - Conditions: Adult Acute Lymphoblastic Leukemia; Adult Acute Myeloid Leukemia; Adult Burkitt Lymphoma; Adult Diffuse Large Cell Lymphoma; Adult Diffuse Mixed Cell Lymphoma; Adult Diffuse Small Cleaved Cell Lymphoma; Adult Hodgkin Lymphoma; Adult Immunoblastic Large Cell Lymphoma; Adult Lymphoblastic Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Breast Cancer; Chronic Eosinophilic Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Cutaneous T-cell Non-Hodgkin Lymphoma; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3 Follicular Lymphoma; Malignant Testicular Germ Cell Tumor; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Multiple Myeloma; Mycosis Fungoides/Sezary Syndrome; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neutropenia; Nodal Marginal Zone B-cell Lymphoma; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Plasma Cell Neoplasm; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Primary Myelofibrosis; Prolymphocytic Leukemia; Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma
Intervention: Drug: cefepime hydrochloride
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Malignant Solid Tumour; Breast Cancer; Ovarian Cancer; Colorectal Cancer
Intervention: Drug: NKTR-102
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Available - verified April 2012 - Condition: Stage IIIC Ovarian Cancer
Interventions: Procedure: Laparoscopy; Procedure: Cytoreduction
Sponsors: Catholic University of the Sacred Heart; Catholic University of the Sacred Heart
Recruiting - verified October 2011 - Condition: Polycystic Ovary Syndrome
Intervention: Behavioral: Structured Lifestyle Education
Sponsors: University of Leicester; University of Leicester; Society for Endocrinology
Recruiting - verified October 2011 - Conditions: CD27 Expressing B-cell Malignancies; CD27 Expressing Solid Tumors; Chronic Lymphocytic Leukemia; Burkett's Lymphoma; Mantle Cell Lymphoma; Primary Lymphoma of the Central Nervous System; Marginal Zone B Cell Lymphoma; Solid Tumor; Metastatic Melanoma; Renal (Clear) Cell Carcinoma; Hormone-refractory Prostate Adenocarcinoma; Ovarian Cancer; Colorectal Adenocarcinoma; Non-small Cell Lung Cancer
Intervention: Drug: CDX-1127
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012 - Conditions: Polycystic Ovary Syndrome; Insulin Resistance
Intervention: Other: Acupuncture
Sponsors: Göteborg University; Göteborg University
Recruiting - verified October 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: pegylated liposomal doxorubicin hydrochloride; Drug: veliparib
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Infertility; Obesity
Intervention: Other: Culture medium metabolomic analysis
Sponsors: Instituto Valenciano de Infertilidad, Spain; Instituto Valenciano de Infertilidad, Spain
Recruiting - verified February 2012 - Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: MM-121 (SAR256212) + Paclitaxel; Drug: Paclitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Hereditary Breast/Ovarian Cancer (brca1, brca2); Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: study of socioeconomic and demographic variables; Procedure: disease screening; Procedure: evaluation of cancer risk factors; Procedure: genitourinary surgical procedure; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified September 2011 - Conditions: Breast Cancer; Ovarian Cancer
Interventions: Drug: AZ2281; Drug: Carboplatin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Anemia; Breast Cancer; Cancer; Colorectal Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Solid Tumors
Intervention:
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Prostate Cancer; Breast Cancer; Lung Cancer; Ovarian Cancer; Lymphoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Intervention: Procedure: Acute Normovolemic Hemodilution
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012 - Condition: Epithelial Ovarian Cancer
Intervention: Other: Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol
Sponsors: University Medical Centre Groningen; University Medical Centre Groningen
Recruiting - verified September 2011 - Conditions: Infertility; PCOS
Interventions: Drug: Metformin, gonadotropins in step-down regimen; Drug: Placebo, gonadotropins in step-up regimen
Sponsors: University Magna Graecia; University Magna Graecia
Not yet recruiting - verified September 2011 - Conditions: Colorectal Cancer With Hepatic Metastases; Pancreas Cancer With Hepatic Metastase; Gastric Cancer With Hepatic Metastase; Breast Cancer With Hepatic Metastase; Ovarian Cancer With Hepatic Metastase
Intervention: Drug: TKM-080301
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Ovarian Cancer
Intervention: Other: culture ex vivo with exposure to different therapeutic agents alone or in combination.
Sponsors: Centre Francois Baclesse; Centre Francois Baclesse; GRECAN
Recruiting - verified May 2012 - Condition: Ovarian Epithelial Cancer
Interventions: Biological: Procure; Biological: Procure
Sponsors: Life Research Technologies GmbH; Life Research Technologies GmbH
Recruiting - verified October 2011 - Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Genetic: DNA methylation analysis; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified September 2011 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Letrozole; Drug: Chinese herbal compound; Drug: Chinese herbal compound placebo
Sponsors: Heilongjiang University of Chinese Medicine; Xiaoke Wu
Recruiting - verified March 2012 - Conditions: Hyperandrogenemia; Polycystic Ovary Syndrome
Interventions: Drug: Progesterone; Drug: Estrace (estrogen)
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Condition: Ovarian Hyperstimulation Syndrome
Interventions: Drug: calcium; Drug: 0.9 % saline
Sponsors: Cairo University; Cairo University
Recruiting - verified November 2011 - Conditions: Polycystic Ovary Syndrome; Hyperandrogenism
Interventions: Drug: Metformin; Drug: Progesterone; Drug: estrace
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Conditions: Polycystic Ovary Syndrome; Hyperandrogenism
Interventions: Drug: Progesterone; Drug: Placebo
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Conditions: Febrile Neutropenia; Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Prostate Cancer; Multiple Myeloma; Bladder Cancer; B-cell Lymphoma
Intervention:
Sponsors: Sandoz; Sandoz
Recruiting - verified October 2011 - Conditions: Polycystic Ovary Syndrome; Hyperandrogenism
Interventions: Drug: Flutamide; Drug: Progesterone; Drug: estrace (estradiol)
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified September 2011 - Conditions: Hyperandrogenemia; Polycystic Ovary Syndrome (PCOS)
Interventions: Drug: estrace; Drug: Progesterone
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Interventions: Drug: Spironolactone; Drug: Dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Hydrocortisone; Drug: dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Interventions: Drug: Metformin; Drug: Dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Condition: Ovarian Cancer
Intervention:
Sponsors: Genentech; Genentech
Not yet recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Polycystic Ovary Syndrome; Obesity
Interventions: Drug: Dexamethasone; Drug: Cortrosyn
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of California, San Diego
Recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Hydrocortisone; Drug: dexamethasone; Drug: Cosyntropin (ACTH)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Leuprolide; Drug: Dexamethasone; Drug: recombinant human chorionic gonadotropin
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Polycystic Ovary Syndrome; Obesity; Hyperandrogenism
Interventions: Drug: Dexamethasone; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia; University of California, San Diego
Recruiting - verified August 2011 - Condition: Ovarian Cancer
Interventions: Other: Pre-study Questionnaire; Other: Educational Presentations; Other: CAM Therapies; Other: Post-study Questionnaire
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; University of South Florida
Recruiting - verified January 2012 - Conditions: Idiopathic Growth Hormone Deficiency; Turner Syndrome
Intervention: Other: Blood sampling
Sponsors: Merck KGaA; Merck KGaA; Merck Serono S.A., Geneva
Recruiting - verified May 2012 - Conditions: Breast Cancer; Ovarian Cancer
Interventions: Drug: 6-Mercaptopurine; Drug: Methotrexate
Sponsors: University of Oxford; University of Oxford
Recruiting - verified September 2011 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Biological: DPX-Survivac; Drug: low dose cyclophosphamide (oral)
Sponsors: ImmunoVaccine Technologies, Inc.; ImmunoVaccine Technologies, Inc.
Recruiting - verified December 2011 - Conditions: Carcinoma, Pancreatic Ductal; Mesothelioma; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Amatuximab (MORab-009)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Premature Ovarian Failure (POF); Incipient Ovarian Failure; Poor Response After Ovarian Hyperstimulation; Early Menopause; Hypergonadotropic Amenorrhea
Intervention:
Sponsors: UMC Utrecht; UMC Utrecht; Erasmus Medical Center; Medical Center Alkmaar; University Medical Centre Groningen; Leiden University Medical Center; Medisch Spectrum Twente; Isala Klinieken; Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.; Amphia Hospital; Deventer Ziekenhuis; Catharina Ziekenhuis Eindhoven; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Academisch Ziekenhuis Maastricht; VU University Medical Center
Recruiting - verified July 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Not yet recruiting - verified July 2011 - Conditions: Ovarian Carcinoma; Relapse
Interventions: Drug: Oxaliplatin; Drug: oxaliplatin
Sponsors: Jules Bordet Institute; Jules Bordet Institute
Recruiting - verified November 2011 - Condition: Polycystic Ovarian Syndrome
Interventions: Drug: Birth control; Drug: Birth control plus Brevail
Sponsors: University of Kansas; Samuel Kim, MD
Recruiting - verified January 2012 - Conditions: Infertility; Breast Cancer
Intervention: Procedure: Random Peri-Areolar Fine Needle Aspiration (RPFNA)
Sponsors: University of Kansas; University of Kansas
Recruiting - verified July 2011 - Conditions: Carcinoma of the Ovary; Fallopian Tube Cancer; Peritoneal Serous-type Advanced Stage
Intervention: Other: blood samples
Sponsors: Centre Francois Baclesse; Centre Francois Baclesse
Recruiting - verified February 2012 - Conditions: Prostate Cancer; Pancreatic Cancer; Melanoma; Renal Cell Carcinoma; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Bladder Cancer; Non-small Cell Lung Cancer; Glioblastoma
Intervention: Biological: MGA271
Sponsors: MacroGenics; MacroGenics
Recruiting - verified December 2011 - Condition: Polycystic Ovary Syndrome
Intervention: Drug: Metformin ER
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; American Diabetes Association
Recruiting - verified July 2011 - Condition: Polycystic Ovary Syndrome
Intervention:
Sponsors: Aristotle University Of Thessaloniki; Aristotle University Of Thessaloniki
Recruiting - verified July 2011 - Condition: Paralytic Ileus
Intervention: Behavioral: Gum chewing
Sponsors: Chiang Mai University; Chiang Mai University
Recruiting - verified January 2012 - Conditions: Infertility; Polycystic Ovary Syndrome
Interventions: Drug: GnRH antagonist (Cetrotide); Drug: Conventional GnRH agonist
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Recruiting - verified July 2011 - Conditions: Renal Cell Carcinoma; Soft Tissue Sarcoma; Glioblastoma; Ovarian Cancer; Cervical Cancer; Breast Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Pancreatic Cancer; Melanoma; Gastrointestinal Cancer
Intervention: Drug: Pazopanib
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; GlaxoSmithKline; Cambridge Experimental Cancer Medicine Centre
Recruiting - verified June 2011 - Conditions: Turner Syndrome; Ovarian Insufficiency
Intervention: Procedure: Ovariectomy
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Groupe Hospitalier Pitie-Salpetriere; Cochin Hospital
Recruiting - verified July 2011 - Conditions: Breast Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms
Interventions: Other: ²¹²Pb-TCMC-Trastuzumab; Biological: trastuzumab
Sponsors: Areva Med LLC; Areva Med LLC
Recruiting - verified January 2012 - Conditions: Lung Cancer; Breast Cancer; Ovarian Cancer
Intervention: Other: exhalation analysis of breath sample
Sponsors: Schillerhoehe Hospital; Schillerhoehe Hospital; Robert Bosch Gesellschaft für Medizinische Forschung mbH
Recruiting - verified November 2011 - Condition: Ovarian Cancer
Intervention: Procedure: Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion
Sponsors: University Hospital, Bonn; University Hospital, Bonn
Recruiting - verified June 2011 - Conditions: Recurrent Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma
Intervention: Biological: Chimeric monoclonal antibody (TRC105) to CD105
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.
Recruiting - verified March 2012 - Conditions: Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Malignant Solid Tumour; Breast Cancer; Malignant Tumor of Colon; GIST; Ovarian Cancer
Intervention: Biological: HER-2 vaccine
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified February 2012 - Condition: Polycystic Ovary Syndrome
Intervention: Drug: Metformin
Sponsors: Biocinese; Biocinese
Recruiting - verified June 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012 - Conditions: Uterine Cancer; Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Cervical Cancer; Vulvar Cancer
Intervention: Other: Survey
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified June 2011 - Condition: Turner Syndrome
Intervention: Drug: somatotropin
Sponsors: University of North Carolina, Chapel Hill; Marsha Davenport, MD; Pfizer
Recruiting - verified January 2012 - Condition: Ovarian Cancer
Interventions: Drug: Carboplatin; Drug: Pegylated Lipoxomal Doxorubicin (PLD); Drug: Trabectedin
Sponsors: Mario Negri Institute for Pharmacological Research; Mario Negri Institute for Pharmacological Research; PharmaMar; Averion International Corporation
Recruiting - verified September 2011 - Condition: Hereditary Breast and Ovarian Cancer Syndrome
Intervention: Behavioral: Inquiry Based Stress Reduction (IBSR) program
Sponsors: Sheba Medical Center; Sheba Medical Center
Recruiting - verified June 2011 - Condition: Non-Small Cell Lung Cancer, Ovarian Cancer
Intervention: Drug: DNIB0600A
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Condition: Polycystic Ovary Syndrome
Intervention: Drug: folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
Sponsors: BC Women's Hospital & Health Centre; BC Women's Hospital & Health Centre; Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Recruiting - verified March 2012 - Condition: Ovarian Cancer
Interventions: Drug: NGR-hTNF; Drug: Pegylated liposomal doxorubicin; Drug: Doxorubicin
Sponsors: MolMed S.p.A.; MolMed S.p.A.
Recruiting - verified December 2011 - Condition: Ovarian Cancer
Interventions: Drug: MK-1775; Drug: Placebo; Drug: paclitaxel; Drug: carboplatin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Interventions: Drug: Panitumumab; Drug: pegylated liposomal doxorubicin (PLD); Drug: Carboplatin
Sponsors: WiSP Wissenschaftlicher Service Pharma GmbH; WiSP Wissenschaftlicher Service Pharma GmbH
Not yet recruiting - verified July 2011 - Conditions: Breast Cancer; Ovarian Cancer; Genetic Predisposition
Intervention: Behavioral: BRCA1/BRCA2 Genetic Counseling
Sponsors: University of Utah; University of Utah; National Cancer Institute (NCI); Huntsman Cancer Institute
Recruiting - verified November 2011 - Condition: Ovarian Cancer
Intervention: Drug: DMUC5754A
Sponsors: Genentech; Genentech
Recruiting - verified July 2011 - Condition: Ovarian Cancer
Intervention:
Sponsors: Eventus Diagnostics Ltd; Eventus Diagnostics Ltd
Not yet recruiting - verified March 2012 - Condition: Ovarian Cancer Recurrent
Interventions: Drug: Ombrabulin (AVE8062); Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Hereditary Breast and Ovarian Cancer Syndrome
Interventions: Genetic: blood collection; Genetic: blood collection
Sponsors: Centre Francois Baclesse; Centre Francois Baclesse
Recruiting - verified February 2012 - Condition: Ovarian Neoplasms
Interventions: Drug: BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; Drug: BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; Drug: BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Recurrent Epithelial Ovarian Cancer
Intervention: Biological: DC-006 vaccine
Sponsors: Oslo University Hospital; Oslo University Hospital
Recruiting - verified January 2012 - Condition: Ovarian Epithelial Cancer Recurrent
Intervention: Procedure: maximal cytoreductive surgery
Sponsors: UNICANCER; UNICANCER
Recruiting - verified June 2011 - Conditions: Marfan Syndrome; Turner Syndrome; Ehlers-Danlos Syndrome; Loeys-Dietz Syndrome; FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation; Bicuspid Aortic Valve Without Known Family History; Bicuspid Aortic Valve With Family History; Bicuspid Aortic Valve With Coarctation; Familial Thoracic Aortic Aneurysm and Dissections; Shprintzen-Goldberg Syndrome; Other Aneurysms and Dissections of the Thoracic Aorta Not Due to Trauma, <50yo; Other Congenital Heart Disease
Intervention:
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 2012 - Condition: Polycystic Ovary Syndrome
Intervention: Other: Weight reduction regimen
Sponsors: Göteborg University; Göteborg University
Recruiting - verified October 2011 - Conditions: Adrenal Hyperplasia; Polycystic Ovarian Syndrome; Oligomenorrhea; Obesity; Hyperandrogenism
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified January 2012 - Conditions: Ovarian Carcinoma; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Biological: OC-DC vaccine; Drug: Bevacizumab; Drug: cyclophosphamide 300 mg/m2/d for 3 days; Drug: fludarabine 30 mg/m2/d for 3 days; Drug: ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified June 2011 - Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; Drug: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; Drug: BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor
Interventions: Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis; Other: immunoenzyme technique; Biological: pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Ovarian Cancer
Interventions: Biological: FANG; Drug: standard of care observational follow-up
Sponsors: Gradalis, Inc.; Gradalis, Inc.
Recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: fosbretabulin tromethamine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Invasive Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer
Intervention: Drug: Propranolol (Inderal)
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: intraperitoneal chemotherapy; Genetic: gene expression analysis; Genetic: protein analysis; Other: flow cytometry; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: TLR8 agonist VTX-2337; Drug: pegylated liposomal doxorubicin hydrochloride; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Intervention: Biological: Panitumumab
Sponsors: Women and Infants Hospital of Rhode Island; Women and Infants Hospital of Rhode Island; Amgen
Recruiting - verified March 2012 - Conditions: Advanced Solid Malignant Tumors; Advanced Ovarian Cancer
Intervention: Drug: U3-1565
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified March 2012 - Conditions: Ovarian Cancer; Uterine Cancer
Interventions: Behavioral: Guided imagery and music therapy; Behavioral: White Noise; Other: No intervention
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Intervention: Drug: MK-2206
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified February 2012 - Conditions: Fallopian Tube Cancer; Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer
Interventions: Drug: everolimus; Drug: carboplatin; Drug: pegylated liposomal doxorubicin hydrochloride; Other: laboratory biomarker analysis
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Primary Peritoneal Neoplasm
Interventions: Biological: KHK2866; Drug: Gemcitabine and Carboplatin; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified February 2012 - Conditions: Mesothelioma; Pancreatic Cancer; Ovarian Cancer; Non-small Cell Lung Cancer
Intervention: Drug: Amatuximab
Sponsors: Morphotek; Morphotek
Recruiting - verified January 2012 - Conditions: Ovarian Hyperstimulation Syndrome; Effects of Gonadotropin; Oocyte Maturation
Interventions: Drug: GnRH antagonist (Cetrorelix); Drug: Placebo (saline solution)
Sponsors: Instituto Valenciano de Infertilidad, Spain; Instituto Valenciano de Infertilidad, Spain
Recruiting - verified March 2012 - Conditions: Infertility, Female; Ovarian Insufficiency
Intervention: Procedure: Direct aspiration needle Echo tip® Cook® single Lumen and Follicular flushing with double lumen needle Echo tip® Cook® Double Lumen Aspiration
Sponsors: University Hospital, Strasbourg, France; University Hospital, Strasbourg, France
Recruiting - verified March 2012 - Conditions: Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Intervention: Other: Narrow Band Imaging (NBI)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012 - Conditions: Ovarian Diseases; Ovarian Neoplasms
Interventions: Other: Laboratory Tumor Marker Analysis; Other: Transvaginal Ultrasound; Other: Health Status Questionnaire
Sponsors: Swedish Medical Center; Swedish Medical Center; Fred Hutchinson Cancer Research Center; The Marsha Rivkin Center for Ovarian Cancer Research
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Intervention: Procedure: surgery or debulking surgery
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified May 2011 - Conditions: Polycystic Ovary Syndrome; Metabolic Syndrome; Cardiovascular Disease
Intervention:
Sponsors: Taipei Medical University WanFang Hospital; Taipei Medical University WanFang Hospital
Recruiting - verified October 2011 - Condition: Polycystic Ovary Syndrome
Intervention:
Sponsors: Taipei Medical University WanFang Hospital; Taipei Medical University WanFang Hospital
Recruiting - verified May 2012 - Conditions: Endometrial Cancer; Ovarian Cancer
Interventions: Drug: Ridaforolimus; Drug: Paclitaxel; Drug: carboplatin
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Merck
Recruiting - verified April 2012 - Conditions: Anal Cancer; Breast Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Lung Cancer; Nonneoplastic Condition; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: carboplatin; Drug: carboplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified November 2011 - Conditions: Pleuropulmonary Blastoma; Cystic Nephroma; Ovarian Sertoli-Leydig Cell Tumors; Ocular Medulloepithelioma; Nasal Chondromesenchymal Hamartoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Conditions: Fallopian Tubes; Ovarian Cancer; Peritoneal Cancer
Intervention: Biological: Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012 - Conditions: Depression; PCOS
Interventions: Dietary Supplement: Inositol; Dietary Supplement: Placebo
Sponsors: AGUNCO Obstetrics and Gynecology Centre; AGUNCO Obstetrics and Gynecology Centre; Centro Clinico Colle Cesarano Tivoli Rome Italy
Recruiting - verified June 2011 - Conditions: Cervical Cancer; Uterus Cancer; Ovarian Cancer
Intervention: Procedure: gynecologic surgery
Sponsors: Centre Oscar Lambret; Centre Oscar Lambret; CRG : Groupe Francophone de Chirurgie Robotique en Gynécologie
Recruiting - verified December 2011 - Conditions: Ovarian Cancer; Peritoneal Metastasis
Intervention: Procedure: intravenous contrast administration
Sponsors: Universitaire Ziekenhuizen Leuven; Universitaire Ziekenhuizen Leuven
Recruiting - verified September 2011 - Condition: Ovarian Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: carboplatin; Drug: Paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Mixed Muellerian Cancer; Cervical Cancer; Ovarian Cancer; Breast Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer; Carcinosarcoma
Interventions: Drug: Carboplatin; Drug: Olaparib; Drug: Treatment Effect
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Conditions: Fallopian Tubes Cancer; Ovarian Cancer; Peritoneal Cancer
Intervention: Biological: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified February 2012 - Conditions: Melanoma; Ovarian Cancer; Sarcoma; BONE; CNS-SPINAL CD/MEMBR,NOS; LYMPH NODES; SOFT TISSUE
Interventions: Radiation: IGIMRT using a single dose of 24 Gy; Radiation: IGIMRT 27 Gy in 3 fractions
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Pisa
Recruiting - verified March 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Step-up HP u FSH; Drug: Clomiphine citrate plus low dose uFSH
Sponsors: Mansoura Integrated Fertility Center; Mansoura Integrated Fertility Center
Recruiting - verified February 2012 - Conditions: Healthy, no Evidence of Disease; Hereditary Breast/Ovarian Cancer - BRCA1; Hereditary Breast/Ovarian Cancer - BRCA2
Interventions: Other: questionnaire administration; Other: survey administration; Other: counseling intervention; Other: educational intervention
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma
Intervention: Drug: Lenalidomide, Liposomal Doxorubicin, Bevacizumab
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance; Celgene Corporation
Recruiting - verified December 2011 - Condition: Ovarian Carcinoma
Intervention: Drug: SJG-136
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: wild-type reovirus; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Breast Cancer; Ovarian Insufficiency; Ovarian Failure
Intervention:
Sponsors: University of California, San Diego; University of California, San Diego; University of Pennsylvania; American Cancer Society; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: Gemcitabine; Drug: Vinorelbine
Sponsors: The Catholic University of Korea; The Catholic University of Korea; Korean Cancer Study Group
Recruiting - verified February 2012 - Conditions: Non-Small Cell Lung Neoplasms; Prostate Neoplasms; Bladder Neoplasms; Ovarian Neoplasms; Breast Neoplasms
Intervention: Drug: MGAH22
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Intervention:
Sponsors: Turku University Hospital; Turku University Hospital
Recruiting - verified January 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: carboplatin; Drug: pralatrexate
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women's Hospital; National Comprehensive Cancer Network
Recruiting - verified April 2012 - Condition: Ovarian Cancer
Intervention:
Sponsors: University of Virginia; University of Virginia
Recruiting - verified May 2011 - Conditions: Fragile X Syndrome; FMR1 Premutation; Primary Ovairan Insufficiency; Premature Ovarian Failure; Premature Menopause
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified July 2011 - Conditions: Ovarian Cancer; Endometrium Cancer
Intervention: Other: SCP care
Sponsors: University of Tilburg; Lonneke van de Poll-Franse; Comprehensive Cancer Centre South (CCCS); Dutch Cancer Society
Recruiting - verified August 2011 - Conditions: Ovarian Cancer; Relapses
Intervention: Drug: Topotecan
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified July 2011 - Condition: Familial Premature Ovarian Failure
Intervention:
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified August 2011 - Condition: Ovarian Cancer
Interventions: Other: Palliative Performance Scale version 2 (PPSv2); Other: McCorkle Symptom Distress Scale (SDS); Other: Geriatric Assessment; Other: Medical Records Abstraction
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Pleural Metastases; Breast Cancer; Colon Cancer; Ovarian Cancer; Uterine Cancer; Renal Cell Cancer; Thymic Cancer
Intervention: Procedure: Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
Sponsors: St. Luke's-Roosevelt Hospital Center; St. Luke's-Roosevelt Hospital Center
Recruiting - verified September 2011 - Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®); Drug: placebo; Drug: EC20
Sponsors: Endocyte; Endocyte
Recruiting - verified March 2012 - Condition: PCOS
Interventions: Drug: Dexamethasone and recombinant hCG; Drug: dexamethasone, human chorionic gonadotrpoin (hCG)
Sponsors: University of California, San Diego; University of California, San Diego; University of Virginia
Recruiting - verified August 2011 - Conditions: Breast Cancer; Gastric Cancer; Bladder Cancer; Ovarian Cancer; Non-small Cell Lung Cancer
Intervention: Biological: MGAH22
Sponsors: MacroGenics; MacroGenics; Green Cross Corporation; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Ovarian Cysts
Interventions: Drug: Ropivacaine nebulization; Drug: Ropivacaine instillation
Sponsors: San Gerardo Hospital; San Gerardo Hospital; Ospedali Riuniti di Bergamo
Recruiting - verified September 2011 - Conditions: Breast Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: quality-of-life assessment; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Biological: Monoclonal antibody Hu3S193
Sponsors: Recepta Biopharma; Recepta Biopharma
Recruiting - verified September 2011 - Conditions: Chemotherapy; Tumor; Ovarian Cancer
Intervention: Biological: OCDC
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Carcinoma
Interventions: Drug: Hyperthermic intraperitoneal chemotherapy with Carboplatin; Other: Isotonic saline (perfusate); Procedure: Surgery; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Conditions: Brain and Central Nervous System Tumors; Breast Cancer; Colorectal Cancer; Kidney Cancer; Lung Cancer; Melanoma (Skin); Ovarian Cancer; Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cediranib maleate; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Intervention: Drug: Carboplatin, paclitaxel, and bevacizumab
Sponsors: Columbia University; Columbia University; Genentech
Recruiting - verified October 2011 - Condition: Epithelial Ovarian Cancer
Interventions: Procedure: CA125 assay on Abbott Architect i1000SR platform; Procedure: HE4 assay on Architect i1000SR platform; Procedure: Transvaginal Ultrasound
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; The Marsha Rivkin Center for Ovarian Cancer Research; Canary Foundation; Swedish Medical Center; Beckman Research Institute; Cedars-Sinai Medical Center; Stanford University; Fox Chase Cancer Center
Recruiting - verified February 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: EGEN-001; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: cediranib; Drug: olaparib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; University of Chicago; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Advanced Cancer; Non Small Cell Lung Cancer; Colorectal Cancer; Ovarian Cancer
Intervention: Drug: LY2606368
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified November 2011 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Letrozole -Berberine; Drug: Letrozole; Drug: Berberine
Sponsors: Heilongjiang University of Chinese Medicine; Heilongjiang University of Chinese Medicine; Ministry of Science and Technology of the People´s Republic of China
Recruiting - verified March 2012 - Condition: Ovarian Neoplasms
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine; University of Iowa
Recruiting - verified October 2011 - Condition: Ovarian Cancer Recurrent
Intervention: Drug: Lenalidomide
Sponsors: ARCAGY/ GINECO GROUP; ARCAGY/ GINECO GROUP
Recruiting - verified February 2011 - Conditions: Infertility; Implantation Failure
Interventions: Procedure: endometrial biopsy; Procedure: endometrial biopsy; Procedure: natural cycle + IUI + endometrial biopsy
Sponsors: Meir Medical Center; Meir Medical Center
Recruiting - verified March 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Breast Cancer
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Cyclosporine; Biological: Natural killer cells; Drug: IL-2; Drug: Methylprednisolone; Drug: Methylprednisolone; Drug: Interleukin-2
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Conditions: Estrogen Receptor-negative Breast Cancer; Hereditary Breast/Ovarian Cancer - BRCA1; Hereditary Breast/Ovarian Cancer - BRCA2; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Other: immunohistochemistry staining method; Genetic: gene expression analysis; Drug: veliparib; Drug: cisplatin; Drug: vinorelbine tartrate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: liposome-encapsulated doxorubicin citrate; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Innsbruck Universitaetsklinik
Recruiting - verified April 2010 - Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified January 2012 - Condition: Ovarian Cancer
Intervention:
Sponsors: Vanderbilt University; Vanderbilt University; National Cancer Institute (NCI); Celgene Corporation
Recruiting - verified April 2012 - Condition: Epithelial Ovarian Cancer
Intervention: Procedure: Seprafilm™
Sponsors: University of British Columbia; University of British Columbia; Genzyme
Recruiting - verified November 2011 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Intervention: Drug: Irinotecan and Bevacizumab
Sponsors: New York University School of Medicine; New York University School of Medicine; Genentech
Recruiting - verified March 2012 - Conditions: Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Cancer; Breast Carcinoma
Interventions: Drug: MLN8237 + Paclitaxel; Drug: MLN8237+Paclitaxel vs. Paclitaxel alone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011 - Conditions: Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Gastrointestinal Complications; Long-term Effects Secondary to Cancer Therapy in Adults; Ovarian Cancer; Prostate Cancer; Radiation Toxicity; Sarcoma; Testicular Germ Cell Tumor; Vaginal Cancer
Interventions: Other: questionnaire administration; Procedure: gastrointestinal complications management/prevention; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust
Recruiting - verified March 2010 - Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: University College, London; University College, London; National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified December 2011 - Conditions: Cognitive/Functional Effects; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: systemic chemotherapy; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Polycystic Ovary Syndrome
Intervention: Behavioral: Nutrition Education, Dietary Counseling, and Cooking
Sponsors: Children's Hospital Boston; Children's Hospital Boston; Thrasher Research Fund
Recruiting - verified June 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: bortezomib; Drug: carboplatin; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Polycystic Ovarian Syndrome
Interventions: Drug: Endometrin (progesterone 100mg vaginal inserts); Drug: Metformin
Sponsors: Yale University; Yale University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012 - Conditions: Ovarian Cancer; Non Small Cell Lung Cancer; Prostate Cancer; Colorectal Cancer; Gastric Cancer; Esophageal Cancer; Cancer of Head and Neck
Interventions: Drug: LY2523355; Drug: pegfilgrastim
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified December 2011 - Condition: Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Carcinoma
Interventions: Drug: Pazopanib; Drug: Doxil
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; GlaxoSmithKline
Recruiting - verified November 2011 - Condition: Ovarian Cancer
Interventions: Behavioral: Interview; Behavioral: Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified April 2012 - Condition: Ovarian Cancer
Intervention: Drug: BSI-201
Sponsors: Sanofi-Aventis; Sanofi-Aventis; BiPar Sciences
Recruiting - verified June 2011 - Conditions: Adult Solid Tumor; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Adult Central Nervous System Germ Cell Tumor; Adult Teratoma; Benign Teratoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Familial Testicular Germ Cell Tumor; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Male Breast Cancer; Ovarian Immature Teratoma; Ovarian Mature Teratoma; Ovarian Monodermal and Highly Specialized Teratoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Extragonadal Seminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Melanoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Rectal Cancer; Stage III Extragonadal Non-seminomatous Germ Cell Tumor; Stage III Extragonadal Seminoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Ovarian Germ Cell Tumor; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Extragonadal Non-seminomatous Germ Cell Tumor; Stage IV Extragonadal Seminoma; Stage IV Melanoma; Stage IV Ovarian Germ Cell Tumor; Stage IV Rectal Cancer; Testicular Immature Teratoma; Testicular Mature Teratoma
Interventions: Drug: PD-0332991; Other: pharmacological study
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified February 2012 - Conditions: Ovarian Cancer; Primary Peritoneal Cavity Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: topotecan hydrochloride; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Ovarian Hyperstimulation Syndrome
Interventions: Drug: Cabergoline; Drug: Control
Sponsors: Royan Institute; Royan Institute
Recruiting - verified November 2009 - Condition: Ovarian Cancer
Intervention: Drug: topotecan and erlotinib
Sponsors: New York University School of Medicine; New York University School of Medicine; OSI Pharmaceuticals
Recruiting - verified February 2012 - Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: Carboplatin; Drug: Pemetrexed
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified July 2011 - Conditions: Fallopian Tube Cancer; Metastatic Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Grupo Español de Investigación en Cáncer de Ovario; Cancer Research UK; Southwestern Oncology Group (SWOG)
Recruiting - verified March 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Radiation: 3-D Ultrasound; Drug: hCG with and without FSH; Drug: Adrenocorticotropin (ACTH) infusion; Drug: Diazoxide and hCG
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified August 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Drug: veliparib
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Ovarian Cancer
Interventions: Other: diagnostic laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry; Procedure: screening method
Sponsors: National Cancer Institute (NCI); Women and Infants Hospital of Rhode Island; National Cancer Institute (NCI)
Recruiting - verified September 2009 - Conditions: Advanced/Recurrent Breast Cancer; Endometrial Cancer; Ovarian Cancer
Intervention: Drug: Temsirolimus/PLD
Sponsors: Radboud University; Radboud University
Recruiting - verified April 2012 - Condition: Ovarian Neoplasms
Interventions: Drug: Vorinostat; Drug: Vorinostat
Sponsors: Gynecologic Oncology Associates; Gynecologic Oncology Associates; Merck
Recruiting - verified June 2011 - Conditions: Polycystic Ovary Syndrome; Insulin Resistance
Interventions: Dietary Supplement: Cinnamon Supplementation; Dietary Supplement: Placebo (wheat flour)
Sponsors: Pennington Biomedical Research Center; Pennington Biomedical Research Center
Recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Other: communication intervention; Other: educational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: management of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Intervention: Dietary Supplement: Lactobacillus rhamnosus GG
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Flutamide; Drug: Placebo
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: Hyperandrogenemia
Interventions: Drug: Micronized progesterone suspension; Drug: Placebo
Sponsors: University of Virginia; University of Virginia; National Institutes of Health (NIH)
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: Vorinostat; Device: Carboplatin; Drug: Gemcitabine
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Merck
Recruiting - verified February 2012 - Condition: Ovarian Cancer
Interventions: Genetic: DNA methylation analysis; Genetic: microarray analysis; Genetic: polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Scottish Gynaecological Cancer Study Group
Recruiting - verified July 2009 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: flow cytometry; Other: immunohistochemistry staining method
Sponsors: National Cancer Institute (NCI); Southeastern Gynecologic Oncology, LLP - Northside
Recruiting - verified July 2009 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel-loaded polymeric micelle
Sponsors: National Cancer Institute (NCI); Asan Medical Center
Recruiting - verified December 2009 - Conditions: Polycystic Ovary Syndrome; In Vitro Fertilization
Interventions: Other: Controlled ovarian hyperstimulation for IVF with a long agonist protocol; Other: Controlled ovarian hyperstimulation for IVF with an antagonist protocol
Sponsors: Institut Universitari Dexeus; Institut Universitari Dexeus
Recruiting - verified October 2010 - Conditions: Ovarian Cancer; Endometrial Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Turner Syndrome
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Institute of Mental Health (NIMH)
Recruiting - verified December 2011 - Conditions: Solid Tumors; Ovarian Cancer
Interventions: Drug: OSI-906; Drug: Paclitaxel
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer; Uterine Cancer; Vaginal Cancer; Vulvar Cancer
Intervention: Behavioral: online platform "STAR" (Symptom Tracking and Reporting for Patients)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified January 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: immunological adjuvant OPT-821; Biological: polyvalent antigen-KLH conjugate vaccine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Intervention: Other: Enteral feeding
Sponsors: Queensland Centre for Gynaecological Cancer; Queensland Centre for Gynaecological Cancer; Cancer Australia; The University of Queensland
Recruiting - verified June 2011 - Conditions: Ovarian Cancer; Breast Cancer
Intervention: Other: screening
Sponsors: New York University School of Medicine; New York University School of Medicine; Lynne Cohen Foundation for Ovarian Cancer Research
Recruiting - verified November 2011 - Condition: Colorectal and Ovarian Cancer Patients With Liver Metastasis
Intervention: Biological: EMD525797
Sponsors: Merck KGaA; Merck KGaA
Recruiting - verified February 2012 - Condition: Ovarian Cancer
Intervention: Biological: DTA-H19
Sponsors: BioCancell Therapeutics Israel Ltd.; BioCancell Therapeutics Israel Ltd.
Recruiting - verified February 2012 - Conditions: Ovarian Cancer; Peritoneal Cavity Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI); National Comprehensive Cancer Network
Recruiting - verified December 2011 - Conditions: Polycystic Ovary Syndrome; Obstructive Sleep Apnea; Obesity
Interventions: Drug: Progesterone; Drug: testosterone; Drug: glucocorticoid; Device: continuous positive airway pressure; Drug: Estrogens
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified February 2012 - Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Intervention: Procedure: Tumor collection
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: GM-CSF; Biological: Dendritic Cell/Tumor Fusion Vaccine; Drug: imiquimod
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Intervention:
Sponsors: University of Virginia; University of Virginia; National Institutes of Health (NIH)
Recruiting - verified May 2012 - Conditions: Cancer; Carcinoma; Fallopian Tube Cancer; Gynecological Malignancies; Metastases; Oncology; Ovarian Cancer; Solid Tumors; Tumors
Interventions: Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin; Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin; Drug: B1: AMG 386 10 mg/kg + Topotecan; Drug: B3: AMG 386 15mg/kg + Topotecan
Sponsors: Amgen; Amgen
Recruiting - verified September 2011 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: ganirelix acetate; Drug: methyl testosterone
Sponsors: Yale University; Yale University
Recruiting - verified August 2011 - Conditions: Cancer; Non-Small Cell Lung Cancer; Endometrial Carcinoma; Ovarian Carcinoma
Interventions: Drug: XL147 (SAR245408),; Drug: paclitaxel; Drug: carboplatin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012 - Conditions: Cervical Cancer; Ovarian Cancer; Uterine Cancer
Intervention: Device: LigaSure vessel sealing system
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012 - Condition: Ovarian Cancer
Interventions: Drug: Bevacizumab; Drug: Carboplatin
Sponsors: Vejle Hospital; Vejle Hospital
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Interventions: Drug: Tranexamic acid; Drug: 0.9% NaCl solution
Sponsors: University Hospital, Linkoeping; Preben Kjolhede
Recruiting - verified November 2011 - Condition: Ovarian Neoplasms
Interventions: Drug: AMG 479; Drug: AMG 479 Placebo
Sponsors: Cancer International Research Group; Cancer International Research Group
Recruiting - verified March 2012 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Intervention:
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified July 2011 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Orlistat (Alli) and Lifestyle Intervention with exercise and diet; Drug: Loestrin 1/20; Drug: Orlistat (Alli) and Loestrin 1/20
Sponsors: Penn State University; Penn State University; University of Pennsylvania
Recruiting - verified November 2011 - Condition: Polycystic Ovary Syndrome
Intervention: Drug: Metformin 500 mg tablet
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University
Recruiting - verified September 2011 - Condition: Ovarian Cancer
Interventions: Biological: Ontak DC; Biological: DC vaccination; Drug: Ontak
Sponsors: Loyola University; Loyola University
Recruiting - verified September 2011 - Condition: Ovarian Cancer
Intervention: Drug: flutamide
Sponsors: University of Arizona; University of Arizona; National Cancer Institute (NCI)
Recruiting - verified September 2010 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: immunological adjuvant OPT-821; Biological: polyvalent antigen-KLH conjugate vaccine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified July 2008 - Conditions: Breast Cancer; Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: Other: counseling intervention; Other: educational intervention; Other: survey administration; Behavioral: psychosocial assessment and care; Behavioral: supportive care
Sponsors: Georgetown University; Georgetown University; National Cancer Institute (NCI); National Human Genome Research Institute (NHGRI)
Recruiting - verified October 2011 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Uterine Neoplasms; Endometrial Cancer; Vaginal Cancer; Vulvar Cancer; Cervical Cancer; Lung Cancer; Carcinoid Tumor of Lung; Sarcoma of Lung; Mesothelioma; Colorectal Cancer
Intervention:
Sponsors: Precision Therapeutics; Precision Therapeutics
Recruiting - verified June 2011 - Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer; Ovarian Cancer
Interventions: Drug: rucaparib (CO-338; formally AG-014699 or PF-01367338); Genetic: protein expression analysis; Genetic: western blotting; Other: immunohistochemistry staining method; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified April 2012 - Condition: Adenocarcinoma of the Ovary
Intervention: Biological: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine
Sponsors: AVAX Technologies; AVAX Technologies
Recruiting - verified January 2011 - Condition: PCOS
Intervention:
Sponsors: University of Pennsylvania; University of Pennsylvania; University of Iowa
Recruiting - verified November 2011 - Conditions: Solid Tumor; Adult Central Nervous System Germ Cell Tumor; Adult Rhabdomyosarcoma; Childhood Central Nervous System Germ Cell Tumor; Childhood Soft Tissue Sarcoma; Ewing Sarcoma; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Ovarian Mixed Germ Cell Tumor; Previously Untreated Childhood Rhabdomyosarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Recurrent Childhood Visual Pathway Glioma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Neuroblastoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: busulfan; Drug: melphalan; Drug: topotecan hydrochloride; Other: laboratory biomarker analysis; Biological: filgrastim; Procedure: autologous hematopoietic stem cell transplantation; Other: pharmacological study; Procedure: autologous bone marrow transplantation
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified November 2011 - Condition: Ovarian Cancer
Intervention:
Sponsors: University of California, Davis; University of California, Davis; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Epithelial Ovarian Cancer; Fallopian Tube Carcinoma
Intervention: Procedure: Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC)
Sponsors: Cantonal Hospital of St. Gallen; Cantonal Hospital of St. Gallen
Recruiting - verified June 2011 - Condition: Ovarian Cancer
Intervention: Other: CA 125 and CT scan
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Johns Hopkins University; M.D. Anderson Cancer Center
Recruiting - verified January 2012 - Conditions: Adrenal Cortical Cancer; Brain Cancer; Breast Cancer; CNS Cancer; Colon Cancer; HEENT Cancer; Hodgkin's Disease; Kaposi's Sarcoma; Liver Cancer; Lung Cancer; Non-Hodgkin's Lymphoma; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Rectal Cancer; Renal Cancer; Sarcoma; Squamous Cell Carcinoma; Thyroid Cancer
Interventions: Device: Proton-decoupled 31P MRS at 1.5T; Device: 1H Spectroscopy at 1.5T and 3T
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Columbia University; University of Pennsylvania; St.George's Hospital (England); Royal Marsden NHS Foundation Trust; University Medical Center Nijmegen; Weill Medical College of Cornell University
Recruiting - verified February 2012 - Conditions: Breast Neoplasms; Ovarian Neoplasms; Colonic Neoplasms; Prostatic Neoplasms; Uterine Cervical Neoplasms; Leukemia; Lymphoma, Non-Hodgkin
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012 - Conditions: Breast Cancer; Ovarian Cancer; Colon Cancer; Benign Disease
Intervention: Other: Tear collection
Sponsors: University of Arkansas; University of Arkansas; Tenenbaum Family Foundation
Recruiting - verified January 2012 - Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Lung Cancer; Melanoma; Non-Hodgkin's Lymphoma; Uterine Cancer; CORPUS UTERI,ENDOMETRIUM; LUNG; OVARY
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012 - Condition: Ovarian Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Ovarian Cancer; Renal Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Solid Tumors; Multiple Myeloma
Intervention: Drug: carfilzomib
Sponsors: Onyx Pharmaceuticals; Onyx Therapeutics, Inc.
Recruiting - verified July 2011 - Conditions: Triple Negative Metastatic Breast Cancer; Advanced Ovarian Cancer; Carboplatin; Paclitaxel
Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor); Drug: Carboplatin; Drug: KU-0059436 (AZD2281)(PARP inhibitor); Drug: Paclitaxel; Drug: KU-0059436 (AZD2281)(PARP inhibitor); Drug: Paclitaxel + Carboplatin
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Peritoneum Tumors
Intervention: Behavioral: Data Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: paclitaxel; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified April 2012 - Conditions: Turner Syndrome; Ovarian Failure, Premature; Sex Chromosome Aberrations; Menopause; Perimenopause
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified October 2009 - Conditions: Anovulation; FHA; Eumenorrhea; Polycystic Ovary Syndrome
Interventions: Procedure: Screening evaluation; Procedure: Meal Response; Genetic: Blood Collection; Procedure: Functional MRI; Procedure: Endocrine Assessment
Sponsors: Emory University; Emory University
Not yet recruiting - verified May 2011 - Conditions: Polycystic Ovary Syndrome; Metabolic Syndrome
Interventions: Drug: Metformin; Drug: flutamide; Drug: drospirenone; Other: placebo
Sponsors: Northwestern University; Northwestern University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2012 - Conditions: Childhood Germ Cell Tumor; Ovarian Cancer; Teratoma
Interventions: Drug: carboplatin; Drug: etoposide; Drug: ifosfamide; Drug: paclitaxel; Drug: thiotepa; Procedure: autologous hematopoietic stem cell transplantation; Drug: Mesna; Biological: filgrastim
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified January 2012 - Condition: Ovarian Cancer
Interventions: Procedure: Secondary debulking; Procedure: secondary debulking with intraperitoneal chemotherapy
Sponsors: The Netherlands Cancer Institute; The Netherlands Cancer Institute
Recruiting - verified April 2012 - Conditions: Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: carcinoembryonic antigen-expressing measles virus; Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Metformin and FSHr; Procedure: Ovarian drilling by FERTILOSCOPY
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Hopital Antoine Beclere; Jean Verdier Hospital (AP-HP); Jean Rostand Intercommoned Hospital; Centre Hospitalier Universitaire, Amiens; University Hospital, Caen; University Hospital, Clermont-Ferrand; Lille Hospital : Jeanne de Flandre Hospital; Strasbourg Hospital : Civil Hospital; SIHCUS-CMCO (Schiltigheim); Study and research center of sterility (Lyon)
Recruiting - verified October 2007 - Conditions: Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Pain; Perioperative/Postoperative Complications; Sarcoma
Interventions: Drug: fentanyl citrate; Drug: hydromorphone hydrochloride; Drug: ropivacaine hydrochloride
Sponsors: National Cancer Institute (NCI); University of California, San Francisco; National Cancer Institute (NCI)
Recruiting - verified September 2007 - Condition: Turner Syndrome
Intervention: Drug: Somatropin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Polycystic Ovary Syndrome
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified September 2011 - Condition: Systemic Lupus Erythematosus
Intervention: Drug: Triptorelin pamoate
Sponsors: FDA Office of Orphan Products Development; FDA Office of Orphan Products Development; Watson Pharmaceuticals
Recruiting - verified August 2011 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin; Biological: therapeutic allogeneic lymphocytes; Drug: mycophenolate mofetil; Drug: cyclosporine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: National Cancer Institute (NCI); Royal College of Obstetricians and Gynecologists
Recruiting - verified May 2007 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Small Lymphocytic Lymphoma
Intervention: Biological: therapeutic allogeneic lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Ovarian Cancer
Interventions: Genetic: comparative genomic hybridization; Genetic: cytogenetic analysis; Genetic: gene rearrangement analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2007 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: ifosfamide; Procedure: hyperthermia treatment
Sponsors: National Cancer Institute (NCI); Ludwig-Maximilians - University of Munich
Recruiting - verified October 2002 - Conditions: Breast Neoplasms; Ovarian Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Ovarian Cancer
Interventions: Other: screening questionnaire administration; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified April 2008 - Condition: Turner's Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012 - Condition: Ovarian Cancer
Intervention: Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: thalidomide
Sponsors: National Cancer Institute (NCI); Cancer Research UK
Recruiting - verified November 2011 - Conditions: Amenorrhea; Hypoaldosteronism; Hypogonadism; Infertility; Premature Ovarian Failure
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified December 2011 - Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Rigshospitalet, Denmark
Recruiting - verified July 2002
 |
Join Clinical Trials That Study Ovary Disorders |
